OTraces completes Phase II testing for blood test that detects breast cancer

OTraces, Inc., a Maryland-based biotech company developing blood tests for cancer diagnosis, announces completion of Phase II testing for a blood test that screens women for breast cancer. The Phase II with the validation tests were conducted at the prestigious Gertsen Institute in Moscow. The initial results represent the first simple blood test for breast cancer with predictive power sufficient for use as a screening diagnostic aid for physicians.

“This test could save time, money, and, most importantly, lives.”

"A blood test to detect breast cancer will improve women's chances of having their cancer diagnosed sooner and then treated successfully," said Keith Lingenfelter, OTraces Chief Executive Officer. "This test could save time, money, and, most importantly, lives."

OTraces has completed significant development for tests for detection of the presence of ovarian and lung cancer. All of these tests are protein-based test panels and show detection predictive power greater than 95%. This predictive power exceeds all currently available diagnostics methods used for these deadly cancers. The company envisions these tests being used in screening people for cancer and for use in conjunction with current diagnostic methods to greatly improve early cancer detection and save lives.